EA202090916A1 - Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией - Google Patents

Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией

Info

Publication number
EA202090916A1
EA202090916A1 EA202090916A EA202090916A EA202090916A1 EA 202090916 A1 EA202090916 A1 EA 202090916A1 EA 202090916 A EA202090916 A EA 202090916A EA 202090916 A EA202090916 A EA 202090916A EA 202090916 A1 EA202090916 A1 EA 202090916A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
acetate
prostate cancer
androgen
abirateron
Prior art date
Application number
EA202090916A
Other languages
English (en)
Inventor
Нампхуонг Тран
Original Assignee
Янссен Онколоджи, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Онколоджи, Инк. filed Critical Янссен Онколоджи, Инк.
Publication of EA202090916A1 publication Critical patent/EA202090916A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описаны способы лечения рака предстательной железы путем применения ацетата абиратерона и преднизона с андроген-депривационной терапией.
EA202090916A 2017-10-11 2018-02-08 Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией EA202090916A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570781P 2017-10-11 2017-10-11
PCT/US2018/017438 WO2019074536A1 (en) 2017-10-11 2018-02-08 METHODS OF TREATING PROSTATE CANCER BY ADMINISTERING ABIRATERONE ACETATE AND PREDNISONE WITH ANDROGENIC SEPARATION THERAPY

Publications (1)

Publication Number Publication Date
EA202090916A1 true EA202090916A1 (ru) 2020-12-11

Family

ID=61283312

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090916A EA202090916A1 (ru) 2017-10-11 2018-02-08 Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией

Country Status (16)

Country Link
US (2) US20190105332A1 (ru)
EP (1) EP3694604A1 (ru)
JP (1) JP2020536903A (ru)
KR (1) KR20200068689A (ru)
CN (1) CN111542373A (ru)
AU (1) AU2018347804A1 (ru)
BR (1) BR112020007090A2 (ru)
CA (1) CA3077678A1 (ru)
EA (1) EA202090916A1 (ru)
IL (1) IL273826A (ru)
JO (1) JOP20200072A1 (ru)
MA (1) MA50341A (ru)
MX (1) MX2020003830A (ru)
PH (1) PH12020550151A1 (ru)
UA (1) UA124865C2 (ru)
WO (1) WO2019074536A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019522032A (ja) 2016-07-29 2019-08-08 ヤンセン ファーマシューティカ エヌ．ベー． 前立腺癌の治療方法
CN115515584A (zh) * 2020-05-08 2022-12-23 詹森药业有限公司 用醋酸阿比特龙和尼拉帕尼的组合治疗前列腺癌

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898495B (zh) * 2012-11-12 2014-11-26 浙江神洲药业有限公司 醋酸阿比特龙酯的制备方法

Also Published As

Publication number Publication date
US20190105332A1 (en) 2019-04-11
KR20200068689A (ko) 2020-06-15
CN111542373A (zh) 2020-08-14
US20200069704A1 (en) 2020-03-05
MA50341A (fr) 2020-08-19
WO2019074536A1 (en) 2019-04-18
MX2020003830A (es) 2020-11-06
EP3694604A1 (en) 2020-08-19
CA3077678A1 (en) 2019-04-18
IL273826A (en) 2020-05-31
JP2020536903A (ja) 2020-12-17
PH12020550151A1 (en) 2021-02-08
AU2018347804A1 (en) 2020-04-16
BR112020007090A2 (pt) 2020-09-24
JOP20200072A1 (ar) 2020-04-29
UA124865C2 (uk) 2021-12-01

Similar Documents

Publication Publication Date Title
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
MX2022007678A (es) Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
JO3606B1 (ar) معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
EA201992430A1 (ru) Комбинированная терапия рака предстательной железы
MX2020001727A (es) Terapia de combinacion.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
GB2568000A (en) Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EA202090916A1 (ru) Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией
MX2016009515A (es) Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2018000135A (es) Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
BR112022022534A2 (pt) Tratamentos de câncer de próstata com combinações de acetato de abiraterona e niraparibe
EA202190294A1 (ru) Комбинированная терапия для лечения рака
MY197942A (en) Adjuvant therapy for use in prostate cancer treatment
EA201891005A1 (ru) Комбинированная терапия рака